Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Clinical trial NCT07686796 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07686796
Sponsor: Guangdong Provincial People's Hospital
Status: NOT_YET_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Local Advanced Rectal Cancer PD-1 Inhibitor PCSK9 Inhibitor RCT Radiotherapy Capecitabine Oxaliplatin

Start date: 2027-01-01
Primary completion: 2030-01-01
Enrollment: 148

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.